Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path

Insmed Incorporated (NASDAQ:INSM) shares are up during Monday’s session following the announcement of positive topline results from the Phase 3b ENCORE study of Arikayce. Symptom Score Gains And Durable Culture Conversion The ENCORE study’s results indicate that Arikayce (amikacin liposome inhalation suspension), in combination with a multidrug therapy, met its primary and all secondary endpoints, showcasing its potential to benefit patients with Mycobacterium avium complex lung infections. MAC lung infection is a chronic, often indolent respiratory illness caused by environmental bacteria (soil/water). The study met primary and all multiplicity-controlled secondary culture conversion endpoints. The trial demonstrated statistically significant and clinically meaningful improvements in respiratory symptom score and culture conversion rates. Insmed Regulatory Filings Planned In 2026 Insmed plans to file a Supplemental NDA with the FDA and submit data to the PMDA in Japan in the second half of 2026 to support potential label changes. In addition to these promising results, the safety profile of ARIKAYCE remained consistent with previous studies, with no new safety signals observed. Analyst Sees Path Toward Approval William Blair notes that while the symptom score improvement did come in slightly below the prior ARISE study at 3.11 points (17.77 versus 14.66 points, p=0.0299), the slides note the improvement increased to 4.8 points by month 15. In addition, Arikayce treatment showed benefit over the control arm at clinically meaningful thresholds of 16.7- and 20.8-point improvements, which was also a key regulatory endpoint for the FDA. Analyst Matt Phipps wrote that the data overall support approval, and the strong culture conversion data, which shows rapid separation by month 2 with continued durability through month 15, will be sufficient to support payer coverage in the frontline setting. Insmed Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $195.71. Recent analyst moves include: Jefferies: Buy (Target $228.00) (Mar. 16) Mizuho: Outperform (Lowers Target to $204.00) (Feb. 24) HC Wainwright & Co.: Buy (Maintains Target to $230.00) (Feb. 23) Insmed Benzinga Edge Rankings Below is the Benzinga Edge scorecard for Insmed, highlighting its strengths and weaknesses compared to the broader market: Momentum: Bullish (Score: 83/100) — Stock is outperforming the broader market. The Verdict: Insmed’s Benzinga Edge signal reveals a strong momentum-driven story, indicating robust performance relative to market trends. This suggests that the stock may continue to attract investor interest as it navigates its upcoming developments. INSM Stock Price Activity: Insmed shares were up 11.03% at $151.00 at the time of publication on Monday, according to Benzinga Pro data. Image via Shutterstock